Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022.
J Natl Compr Canc Netw
; 19(12): 1382-1394, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902824
2.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(10): 1181-1201, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34666313
3.
Circulating neutrophil extracellular trap (NET)-forming 'rogue' neutrophil subset, immunotype [DEspR+CD11b+], mediate multi-organ failure in COVID-19 - an observational study.
Res Sq
; 2023 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36778407
4.
Circulating neutrophil extracellular trap (NET)-forming 'rogue' neutrophil subset, immunotype [DEspR + CD11b +], mediate multi-organ failure in COVID-19-an observational study.
Transl Med Commun
; 8(1): 12, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37096233
5.
"Rogue" [DEspR+CD11b+] neutrophil subset correlates with severity in spontaneous intracerebral hemorrhage.
Front Neurol
; 13: 935579, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35959408
6.
A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.
Cancer Res
; 82(14): 2625-2639, 2022 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657206
7.
A targetable 'rogue' neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS.
Sci Rep
; 12(1): 5583, 2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379853
8.
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Nat Commun
; 13(1): 1381, 2022 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296667
9.
Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.
Res Sq
; 2021 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34545358
10.
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
J Invest Dermatol
; 140(11): 2242-2252.e7, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389536
11.
In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.
Mol Cancer Ther
; 18(9): 1637-1648, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270153
12.
C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo.
Pigment Cell Melanoma Res
; 32(6): 829-841, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31251472